Lead Sponsor

University of Manchester

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

No

•at least 18 years of age and
•Have a confirmed diagnosis of oHCM that is not solely explained by abnormal loading conditions such as significant hypertension or valvular disease
•Qualify for mavacamten therapy by exhibiting a peak Left Ventricular Outflow Tract (LVOT) gradient of ≥ 50mmHg at rest or with provocation, New York Heart Association (NYHA) functional class II or III symptoms, and a baseline Left Ventricular Ejection Fraction (LVEF) of ≥ 55%

•HCM phenocopies such as cardiac amyloidosis or Fabry's disease
•Undergone a septal reduction therapy (myectomy or ablation) within the preceding 6 months
•Any contraindications to mavacamten (e.g., baseline LVEF \< 55%, pregnancy/breastfeeding)
•Inability to safely undergo a cardiac MRI, such as having non-compatible metal implants or severe claustrophobia